Continued Access to RXDX-105

Memorial Sloan Kettering Cancer Center (MSK)

Status and phase: Completed; Phase 1

Conditions: RET Gene Mutation; Non Small Cell Lung Cancer; Ovarian Cancer; BRAF Gene Mutation

Treatments: Drug: RXDX-105

Study type: Interventional

Funder types: Other

Identifiers

NCT03784378

18-487

Details and patient eligibility

About

This study is being done to see if people with Non-Small Cell Lung Cancer (NSCLC) or ovarian cancer benefit from continued treatment with the study drug, RXDX-105.

Enrollment: 3 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• This individual patient protocol includes treatment for 3 patients previously enrolled on IRB #15-270 (phase1/1b clinical trial RXDX-105-01):

Exclusion criteria

• Any patients other than those described above are excluded.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

3 participants in 1 patient group

Participants previously enrolled on Study of RXDX-105

Experimental group

Description:

Participants were previously enrolled on Study of RXDX-105

Treatment:

Drug: RXDX-105